Cargando…

The Relative Expression of Mig6 and EGFR Is Associated with Resistance to EGFR Kinase Inhibitors

The sensitivity of only a few tumors to anti-epidermal growth factor receptor EGFR tyrosine kinase inhibitors (TKIs) can be explained by the presence of EGFR tyrosine kinase (TK) domain mutations. In addition, such mutations were rarely found in tumor types other than lung, such as pancreatic and he...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Xiaofei, Izumchenko, Eugene, Solis, Luisa M., Kim, Myoung Sook, Chatterjee, Aditi, Ling, Shizhang, Monitto, Constance L., Harari, Paul M., Hidalgo, Manuel, Goodman, Steve N., Wistuba, Ignacio I., Bedi, Atul, Sidransky, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3729565/ https://www.ncbi.nlm.nih.gov/pubmed/23935914 http://dx.doi.org/10.1371/journal.pone.0068966

Ejemplares similares

The Antitumorigenic Function of EGFR in Metastatic Breast Cancer is Regulated by Expression of Mig6
por: Wendt, Michael K., et al.
Publicado: (2015)

Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
por: Kang, Da Hyun, et al.
Publicado: (2020)

Adenylate Kinase 3 Sensitizes Cells to Cigarette Smoke Condensate Vapor Induced Cisplatin Resistance
por: Chang, Xiaofei, et al.
Publicado: (2011)

Amelioration of Hypercholesterolemia by an EGFR Tyrosine Kinase Inhibitor in Mice with Liver-Specific Knockout of Mig-6
por: Lee, Jun Choul, et al.
Publicado: (2014)

PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells
por: Siu, Allan, et al.
Publicado: (2011)

Glucolipotoxic Stress-Induced Mig6 Desensitizes EGFR Signaling and Promotes Pancreatic Beta Cell Death
por: Chen, Yi-Chun, et al.
Publicado: (2023)

A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via kinase suppression and receptor degradation
por: Frosi, Yuri, et al.
Publicado: (2010)

Understanding the molecular basis of EGFR kinase domain/MIG-6 peptide recognition complex using computational analyses
por: Moonrin, Ninnutt, et al.
Publicado: (2015)

Altered Expression of Three EGFR Posttranslational Regulators MDGI, MIG6, and EIG121 in Invasive Breast Carcinomas
por: Meseure, Didier, et al.
Publicado: (2020)

Intervention of AXL in EGFR Signaling via Phosphorylation and Stabilization of MIG6 in Non-Small Cell Lung Cancer
por: Yang, Ya-Yu, et al.
Publicado: (2023)

Honokiol Prevents Non-Alcoholic Steatohepatitis-Induced Liver Cancer via EGFR Degradation through the Glucocorticoid Receptor—MIG6 Axis
por: Okuda, Keiichiro, et al.
Publicado: (2021)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen, Miaomiao, et al.
Publicado: (2018)

Combinatorial control of gene expression by the three yeast repressors Mig1, Mig2 and Mig3
por: Westholm, Jakub Orzechowski, et al.
Publicado: (2008)

Lung cancer stem cells and their aggressive progeny, controlled by EGFR/MIG6 inverse expression, dictate a novel NSCLC treatment approach
por: Xiao, Zhiguang, et al.
Publicado: (2019)

EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors
por: Yang, Jiyoul, et al.
Publicado: (2018)

Roles of Candida albicans Mig1 and Mig2 in glucose repression, pathogenicity traits, and SNF1 essentiality
por: Lagree, Katherine, et al.
Publicado: (2020)

Correction: Lung cancer stem cells and their aggressive progeny, controlled by EGFR/MIG6 inverse expression, dictate a novel NSCLC treatment approach
por: Xiao, Zhiguang, et al.
Publicado: (2021)

Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA
por: Izumchenko, Evgeny, et al.
Publicado: (2015)

Cysteine Dioxygenase 1 Is a Tumor Suppressor Gene Silenced by Promoter Methylation in Multiple Human Cancers
por: Brait, Mariana, et al.
Publicado: (2012)

EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR
por: Jo, Ukhyun, et al.
Publicado: (2014)

Clathrin‐mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild‐type EGFR non‐small cell lung cancer
por: Kim, Boyeon, et al.
Publicado: (2020)

Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR(WT), EGFR(T790M), and EGFR(L858R))
por: Abo Al-Hamd, Mahmoud G., et al.
Publicado: (2023)

Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy
por: Ravi, Rajani, et al.
Publicado: (2018)

Brk/PTK6 Sustains Activated EGFR Signaling through Inhibiting EGFR Degradation and Transactivating EGFR
por: Li, X, et al.
Publicado: (2012)

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth
por: Yao, Nan, et al.
Publicado: (2020)

Polymorphisms, Mutations, and Amplification of the EGFR Gene in Non-Small Cell Lung Cancers
por: Nomura, Masaharu, et al.
Publicado: (2007)

EGFR-TKIs resistance via EGFR-independent signaling pathways
por: Liu, Qian, et al.
Publicado: (2018)

EGFR-AS1 Promotes Bladder Cancer Progression by Upregulating EGFR
por: Wang, Anbang, et al.
Publicado: (2020)

The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2016)

Evaluating glaucoma surgeries in the MIGS context
por: Dhingra, Deepika, et al.
Publicado: (2020)

Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer
por: Park, Silvia, et al.
Publicado: (2015)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
por: Wang, Fen, et al.
Publicado: (2012)

Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
por: Wei, Zhigang, et al.
Publicado: (2017)

Expanding the Therapeutic Window of EGFR-Targeted PE24 Immunotoxin for EGFR-Overexpressing Cancers by Tailoring the EGFR Binding Affinity
por: Jun, Sei-Yong, et al.
Publicado: (2022)

EGFR/Met association regulates EGFR TKI resistance in breast cancer
por: Mueller, Kelly L, et al.
Publicado: (2010)

EGFR and mTOR as therapeutic targets in glioblastoma
por: Ronellenfitsch, Michael W., et al.
Publicado: (2019)

The Use of HPV16-E5, EGFR, and pEGFR as Prognostic Biomarkers for Oropharyngeal Cancer Patients
por: Taberna, Miren, et al.
Publicado: (2018)

Including Total EGFR Staining in Scoring Improves EGFR Mutations Detection by Mutation-Specific Antibodies and EGFR TKIs Response Prediction
por: Wu, Shang-Gin, et al.
Publicado: (2011)

Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment
por: Kuiper, J L, et al.
Publicado: (2016)

Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
por: Della Corte, Carminia Maria, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gu024kufbqcfri8p3lftgnqemc